346 related articles for article (PubMed ID: 23331464)
1. Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications.
Shao YH; Moore DF; Shih W; Lin Y; Jang TL; Lu-Yao GL
BJU Int; 2013 May; 111(5):745-52. PubMed ID: 23331464
[TBL] [Abstract][Full Text] [Related]
2. Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States.
Beebe-Dimmer JL; Cetin K; Shahinian V; Morgenstern H; Yee C; Schwartz KL; Acquavella J
Pharmacoepidemiol Drug Saf; 2012 Jan; 21(1):70-8. PubMed ID: 22114014
[TBL] [Abstract][Full Text] [Related]
3. Association of Bone Mineral Density Testing With Risk of Major Osteoporotic Fractures Among Older Men Receiving Androgen Deprivation Therapy to Treat Localized or Regional Prostate Cancer.
Suarez-Almazor ME; Pundole X; Cabanillas G; Lei X; Zhao H; Elting LS; Lopez-Olivo MA; Giordano SH
JAMA Netw Open; 2022 Apr; 5(4):e225432. PubMed ID: 35363269
[TBL] [Abstract][Full Text] [Related]
4. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.
Malcolm JB; Derweesh IH; Kincade MC; DiBlasio CJ; Lamar KD; Wake RW; Patterson AL
Can J Urol; 2007 Jun; 14(3):3551-9. PubMed ID: 17594745
[TBL] [Abstract][Full Text] [Related]
5. Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.
Wu CT; Yang YH; Chen PC; Chen MF; Chen WC
Osteoporos Int; 2015 Sep; 26(9):2281-90. PubMed ID: 25990353
[TBL] [Abstract][Full Text] [Related]
6. Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.
Nguyen C; Lairson DR; Swartz MD; Du XL
Pharmacotherapy; 2018 Oct; 38(10):999-1009. PubMed ID: 30080934
[TBL] [Abstract][Full Text] [Related]
7. Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand.
Wang A; Obertová Z; Brown C; Karunasinghe N; Bishop K; Ferguson L; Lawrenson R
BMC Cancer; 2015 Nov; 15():837. PubMed ID: 26525985
[TBL] [Abstract][Full Text] [Related]
8. Risk of fracture after androgen deprivation for prostate cancer.
Shahinian VB; Kuo YF; Freeman JL; Goodwin JS
N Engl J Med; 2005 Jan; 352(2):154-64. PubMed ID: 15647578
[TBL] [Abstract][Full Text] [Related]
9. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy.
Krupski TL; Smith MR; Lee WC; Pashos CL; Brandman J; Wang Q; Botteman M; Litwin MS
Cancer; 2004 Aug; 101(3):541-9. PubMed ID: 15274067
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer.
Ito K; Elkin EB; Girotra M; Morris MJ
Ann Intern Med; 2010 May; 152(10):621-9. PubMed ID: 20479027
[TBL] [Abstract][Full Text] [Related]
11. Bone health management in prostate cancer patients receiving androgen deprivation therapy.
Dhanapal V; Reeves DJ
J Oncol Pharm Pract; 2012 Mar; 18(1):84-90. PubMed ID: 21807761
[TBL] [Abstract][Full Text] [Related]
12. Androgen deprivation therapy and fracture risk in Chinese patients with prostate carcinoma.
Lee CH; Huang G; Chan PH; Hai J; Yeung CY; Fong CH; Woo YC; Ho KL; Yiu MK; Leung F; Lau TW; Tse HF; Lam KS; Siu CW
PLoS One; 2017; 12(2):e0171495. PubMed ID: 28158241
[TBL] [Abstract][Full Text] [Related]
13. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a prognostic index for fracture risk in older men undergoing prostate cancer treatment.
Graham-Steed TR; Soulos PR; Dearing N; Concato J; Tinetti ME; Gross CP
J Geriatr Oncol; 2014 Oct; 5(4):343-51. PubMed ID: 25240918
[TBL] [Abstract][Full Text] [Related]
15. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
[TBL] [Abstract][Full Text] [Related]
16. Fracture risk in patients with prostate cancer on androgen deprivation therapy.
López AM; Pena MA; Hernández R; Val F; Martín B; Riancho JA
Osteoporos Int; 2005 Jun; 16(6):707-11. PubMed ID: 15714259
[TBL] [Abstract][Full Text] [Related]
17. Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy.
Morgans AK; Smith MR; O'Malley AJ; Keating NL
Cancer; 2013 Feb; 119(4):863-70. PubMed ID: 23065626
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy.
Sun M; Choueiri TK; Hamnvik OP; Preston MA; De Velasco G; Jiang W; Loeb S; Nguyen PL; Trinh QD
JAMA Oncol; 2016 Apr; 2(4):500-7. PubMed ID: 26720632
[TBL] [Abstract][Full Text] [Related]
19. Fracture risk in androgen deprivation therapy: a Canadian population based analysis.
Lau YK; Lee E; Prior HJ; Lix LM; Metge CJ; Leslie WD
Can J Urol; 2009 Dec; 16(6):4908-14. PubMed ID: 20003666
[TBL] [Abstract][Full Text] [Related]
20. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
Diamond TH; Higano CS; Smith MR; Guise TA; Singer FR
Cancer; 2004 Mar; 100(5):892-9. PubMed ID: 14983482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
